TERT and neoplasm: Although BRAFVal600Glu as a tumor driver event alone may not significantly affect patient outcome, its co-existence with the TERT promoter mutation results in the formation of aggressive PTC and even promotes the evolution of PTC to poor-differentiated tumors or ATCs [118,119].